Guided Cartilage Regeneration Membrane

NCT ID: NCT04463238

Last Updated: 2020-07-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-03

Study Completion Date

2023-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Guided cartilage regeneration membrane for repairing the safety and effectiveness of articular cartilage injury

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MRI evaluation using guided cartilage regeneration membrane for articular cartilage injury repair 730 days (2 years) is the main indicator of this trial. In this experiment, we observe the improvement of Lysholm score, VAS score, ratio change of regenerated cartilage T2 value to normal cartilage T2 value, and ratio of regenerated cartilage △R1 value to normal cartilage △R1 value Indicators such as value changes are secondary evaluation indicators.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Articular Cartilage Injury Knee Ligament Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

GCRM-3020\\GCRM-4030
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cartilage membrane surgery

The test group applied the guidance provided by Shaanxi Baiao Regenerative Medicine Co., Ltd.

Cartilage regeneration membrane combined with microfracture surgery.

Group Type EXPERIMENTAL

Guided cartilage regeneration membrane

Intervention Type COMBINATION_PRODUCT

On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.

Microfracture

Intervention Type PROCEDURE

Operate in accordance with the clinical microfracture surgery method.

Microfracture

The control group was treated with microfractures widely recognized at home and abroad.

Group Type OTHER

Microfracture

Intervention Type PROCEDURE

Operate in accordance with the clinical microfracture surgery method.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Guided cartilage regeneration membrane

On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.

Intervention Type COMBINATION_PRODUCT

Microfracture

Operate in accordance with the clinical microfracture surgery method.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥18 years old and ≤50 years old, regardless of gender
2. 2 cm2 ≤ articular cartilage defect repair area ≤ 8 cm2, patients with feasible micro-fractures, no contraindications to surgery
3. Patients voluntarily participate in clinical trials, sign informed consent forms, and can cooperate with clinical follow-up

Exclusion Criteria

1. Those who have participated in clinical trials of other drugs or medical devices in the last 6 months
2. Those with stage III or above degeneration of bone and joint
3. Those who cannot accept pig-derived devices or have special religious beliefs due to religion, ethnicity and other issues
4. Those who are sensitive to collagen, foreign protein or pig-derived materials
5. Repair the damaged area\> 8 cm2 or \<2 cm2, lack of normal cartilage tissue around the injury
6. Severe heart, liver and kidney insufficiency are defined as:

Heart function: NYHA grade III or above; ALT, AST\> 2.5 times the upper limit of normal value; Serum creatinine\> 1.5 times the upper limit of normal value;
7. People with systemic immune diseases or systemic or local infections
8. Joint fibrosis, joint stiffness, and obviously restricted movement
9. Those with moderate or severe osteoarthritis
10. People with contraindications for MRI examination
11. Patients with hemophilia
12. Those who cannot tolerate surgery
13. Women who are pregnant or plan to become pregnant and breastfeeding women
14. Persons with mental abnormalities and incapacity to act autonomously
15. Other conditions that the doctor judges cannot participate in the trial
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhongnan Hospital

OTHER

Sponsor Role collaborator

Second Hospital of Shanxi Medical University

OTHER

Sponsor Role collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

Sponsor Role collaborator

First Affiliated Hospital of Kunming Medical University

OTHER

Sponsor Role collaborator

Zunyi Medical College

OTHER

Sponsor Role collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

Sponsor Role collaborator

Chinese PLA General Hospital

OTHER

Sponsor Role collaborator

Xi'an Honghui Hospital

OTHER

Sponsor Role collaborator

Peking University Third Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yingfang Ao, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Sports Medicine, Peking University Third Hospital

Xiaoqing Hu, PhD

Role: STUDY_DIRECTOR

Department of Sports Medicine, Peking University Third Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Site Status

Zunyi Medical College

Zunyi, Guizhou, China

Site Status

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Site Status

Zhongnan Hospital

Wuhan, Hubei, China

Site Status

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China

Site Status

Second Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Site Status

Xi'an Honghui Hospital

Xi’an, Shanxi, China

Site Status

The First Affiliated Hospital of Kunming Medical College

Kunming, Yunnan, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yingfang Ao, PhD

Role: CONTACT

13401096777 ext. 13401096777

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zhongli Li, PhD

Role: primary

Yi Liu, Bachelor

Role: primary

Jianzhong Xu, PhD

Role: primary

Liaobin Chen, PhD

Role: primary

Qing Jiang, PhD

Role: primary

Zhiqiang Zhang, Postgraduate

Role: primary

Jiang Zheng, PhD

Role: primary

Yanlin Li, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015035

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.